Overview
The most publicly contested molecule in aging research. A 2013 paper reported that GDF-11 declines with age and that restoring it rejuvenates heart, muscle and brain in mice. Subsequent work from other groups found the opposite on several points, including the direction of the age-related change.
Not approved for human use anywhereNo approval anywhere for human use. Sold under research-use labelling. Not approved for human use.
| Regulatory status | Preclinical research protein. No human trials. Not approved. Its central claims are scientifically contested. |
|---|---|
| Drug class | TGF-beta superfamily protein, closely homologous to myostatin (GDF-8) |
| Route | Intraperitoneal or subcutaneous (research) |
| Half-life | Short; circulates bound to latency proteins |
| Evidence rating |
1/5 Minimal
Evidence rating 1 out of 5: Minimal
Animal or laboratory data only. No human efficacy evidence. |
| Studied in | Mouse parabiosis and supplementation studies with directly conflicting results across laboratories. No human interventional trials. |
How it works
Signals through activin type II receptors and SMAD2/3, sharing roughly 90% sequence identity with myostatin in its mature domain. That homology is central to the controversy: assays that could not distinguish GDF-11 from myostatin were used in the original work.
Evidence base
Rated 1 of 5 — Minimal. Animal or laboratory data only. No human efficacy evidence.
- A genuine and unresolved scientific controversy. Any source presenting the rejuvenation claims as established is not describing the current literature.
Benefits & potential uses
Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.
-
Reported cardiac rejuvenation in mice Preliminary
The original work described reversal of age-related cardiac hypertrophy in aged mice given GDF-11.
-
Reported neurogenesis and vascular effects Preliminary
Follow-up work from the same group described improved cerebral vasculature and neurogenesis.
-
Genuine developmental role Moderate evidence
GDF-11 is unambiguously important in embryonic axial patterning — that part is not disputed.
Risks, cons & cautions
Bars indicate seriousness: three = serious or common, two = moderate, one = minor.
-
Core findings contested by independent groups Serious
Other laboratories reported that GDF-11 does not decline with age, and that supplementation inhibits rather than promotes muscle regeneration. This is an active scientific dispute, not settled science.
-
Assay cross-reactivity problem Serious
Because GDF-11 and myostatin are so similar, several early measurements may have been detecting myostatin instead.
-
Muscle atrophy in some studies Serious
Given the myostatin homology, GDF-11 may suppress muscle growth — the opposite of what the anti-aging framing implies.
-
Cachexia signals Serious
High GDF-11 levels have been associated with frailty and cachexia in some human observational work.
-
No human data Serious
No trials, no dosing, no safety characterisation.
-
Sold as a research chemical Serious
Marketed on the strength of the disputed 2013 findings, with the contradicting literature unmentioned.
Who should avoid it
- All human use — the underlying science is unresolved and the direction of effect is disputed
If used under medical supervision, monitor
- Not applicable
Commonly confused with
These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.
Follistatin inhibits myostatin and activins to increase muscle. GDF-11 is myostatin-like and may reduce it. They are marketed adjacently but may act in opposite directions.
Compare side by sideRegulatory & legal status
Not approved for human use.
Infographic
Where to read further
We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.
- PubMed — all published literature on GDF-11
- PubMed — randomized controlled trials only
- ClinicalTrials.gov — registered human trials
Related peptides in Longevity & Mitochondrial
Terms used on this page
- Myostatin
- Myostatin is a muscle-secreted member of the TGF-beta family that acts as a brake on muscle growth, and blocking it enlarges muscle far more reliably than it improves function.
- Neurogenesis
- Neurogenesis is the generation of new neurons from neural stem and progenitor cells, which in the adult mammalian brain is confined to a small number of restricted niches.
- Muscle Hypertrophy
- Muscle hypertrophy is an increase in the cross-sectional area of existing muscle fibres through net accumulation of contractile protein, rather than an increase in fibre number.
This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.